| Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis A Tsapas, I Avgerinos, T Karagiannis, K Malandris, A Manolopoulos, ... Annals of internal medicine 173 (4), 278-286, 2020 | 273 | 2020 |
| Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis T Karagiannis, I Avgerinos, A Liakos, S Del Prato, DR Matthews, A Tsapas, ... Diabetologia 65 (8), 1251-1261, 2022 | 149 | 2022 |
| Semaglutide for type 2 diabetes mellitus: a systematic review and meta‐analysis P Andreadis, T Karagiannis, K Malandris, I Avgerinos, A Liakos, ... Diabetes, Obesity and Metabolism 20 (9), 2255-2263, 2018 | 115 | 2018 |
| Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta‐analysis A Tsapas, T Karagiannis, P Kakotrichi, I Avgerinos, C Mantsiou, ... Diabetes, Obesity and Metabolism 23 (9), 2116-2124, 2021 | 111 | 2021 |
| GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis T Karagiannis, A Tsapas, E Athanasiadou, I Avgerinos, A Liakos, ... Diabetes Research and Clinical Practice 174, 108737, 2021 | 95 | 2021 |
| Oral semaglutide for type 2 diabetes: A systematic review and meta‐analysis I Avgerinos, T Michailidis, A Liakos, T Karagiannis, DR Matthews, ... Diabetes, Obesity and Metabolism 22 (3), 335-345, 2020 | 84 | 2020 |
| Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta‐analysis C Mantsiou, T Karagiannis, P Kakotrichi, K Malandris, I Avgerinos, ... Diabetes, Obesity and Metabolism 22 (10), 1857-1868, 2020 | 61 | 2020 |
| Glucagon‐like peptide‐1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta‐analysis I Avgerinos, T Karagiannis, K Malandris, A Liakos, M Mainou, E Bekiari, ... Diabetes, Obesity and Metabolism 21 (1), 188-193, 2019 | 42 | 2019 |
| Comparative efficacy and safety of glucose‐lowering drugs as adjunctive therapy for adults with type 1 diabetes: a systematic review and network meta‐analysis I Avgerinos, A Manolopoulos, T Michailidis, K Kitsios, A Liakos, ... Diabetes, Obesity and Metabolism 23 (3), 822-831, 2021 | 26 | 2021 |
| Sotagliflozin for patients with type 2 diabetes: a systematic review and meta‐analysis I Avgerinos, T Karagiannis, P Kakotrichi, T Michailidis, A Liakos, ... Diabetes, Obesity and Metabolism 24 (1), 106-114, 2022 | 25 | 2022 |
| Ultra‐rapid‐acting insulins for adults with diabetes: A systematic review and meta‐analysis I Avgerinos, G Papanastasiou, T Karagiannis, T Michailidis, A Liakos, ... Diabetes, Obesity and Metabolism 23 (10), 2395-2401, 2021 | 24 | 2021 |
| GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials A Tsapas, T Karagiannis, I Avgerinos, A Liakos, E Bekiari Diabetes Research and Clinical Practice 177, 108921, 2021 | 19 | 2021 |
| Decision aids for people with Type 2 diabetes mellitus: an effectiveness rapid review and meta‐analysis T Karagiannis, P Andreadis, A Manolopoulos, K Malandris, I Avgerinos, ... Diabetic Medicine 36 (5), 557-568, 2019 | 17 | 2019 |
| Intravenous immunoglobulin for patients with Alzheimer’s disease: a systematic review and meta-analysis A Manolopoulos, P Andreadis, K Malandris, I Avgerinos, T Karagiannis, ... American Journal of Alzheimer's Disease & Other Dementias® 34 (5), 281-289, 2019 | 15 | 2019 |
| Patients’ and clinicians’ preferences on outcomes and medication attributes for type 2 diabetes: a mixed-methods study T Karagiannis, I Avgerinos, M Toumpalidou, A Liakos, K Kitsios, ... Journal of General Internal Medicine, 1-8, 2020 | 13 | 2020 |
| cardiovascular risk reduction in type 2 diabetes: therapeutic potential of dapagliflozin I Avgerinos, A Liakos, A Tsapas, E Bekiari Diabetes, metabolic syndrome and obesity: targets and therapy, 2549-2557, 2019 | 11 | 2019 |
| Racial, ethnic and sex disparities among participants in cardiovascular outcomes trials in type 2 diabetes: A systematic review and descriptive analysis. I Avgerinos, T Karagiannis, A Liakos, A Tsapas, E Bekiari Diabetes, Obesity & Metabolism 25 (2), 2023 | 6 | 2023 |
| Effects of sodium‐glucose co‐transporter‐2 inhibitors by background cardiovascular medications: A systematic review and meta‐analysis I Avgerinos, T Karagiannis, DR Matthews, A Tsapas, E Bekiari Diabetes, Obesity and Metabolism 25 (10), 3020-3029, 2023 | 4 | 2023 |
| Comparative effectiveness of glucose-lowering drugs for type 2 diabetes A Tsapas, T Karagiannis, I Avgerinos, DR Matthews, E Bekiari Annals of Internal Medicine 174 (1), 141, 2021 | 4 | 2021 |
| Management of type 2 diabetes in the new era A Liakos, T Karagiannis, I Avgerinos, K Malandris, A Tsapas, E Bekiari Hormones 22 (4), 677-684, 2023 | 3 | 2023 |
